Stay updated on Venetoclax Combo vs Low Dose Cytarabine in AML Clinical Trial
Sign up to get notified when there's something new on the Venetoclax Combo vs Low Dose Cytarabine in AML Clinical Trial page.

Latest updates to the Venetoclax Combo vs Low Dose Cytarabine in AML Clinical Trial page
- Check3 days agoChange DetectedThe site revision label in the page footer changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe study page now displays a 403 Forbidden error instead of the study details, indicating restricted access to the content.SummaryDifference21%

- Check24 days agoChange DetectedRevision: v3.7.0 was added to the study documents section, replacing the previous Revision: v3.6.6.SummaryDifference0.0%

- Check38 days agoChange DetectedRevision: v3.6.6 has been added and the previous Revision: v3.6.5 has been removed, indicating a minor update to the page's underlying build.SummaryDifference0.0%

- Check45 days agoChange DetectedAn NIH grant/contract attribution for 2016 was added to the study's identifiers. This documents the funding source supporting the trial.SummaryDifference0.0%

- Check60 days agoChange DetectedRevision: v3.6.5 replaces v3.6.4 on the page, representing a small update to the page's revision metadata.SummaryDifference0.0%

Stay in the know with updates to Venetoclax Combo vs Low Dose Cytarabine in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Venetoclax Combo vs Low Dose Cytarabine in AML Clinical Trial page.